Colorectal cancer (CRC), for example, usually starts with mutations in APC, a negative regulator of the Wnt signaling pathway [1]–[3] followed, in ∼50% of CRC patients, by the oncogenic activation of K-Ras, an event that correlates with the onset of malignancy [4]. The gene discussed is KRAS; the disease is colorectal carcinoma.